The accelerated Phase 3 enrollment and expanded trial size are positive signals for the atebimetinib program, but the increased cash burn rate (cash down $50.9M from year-end 2025) and shortened runway to Q4 2028 (from prior into 2029) suggest the company may need to raise capital before the mid-2028 data readout. Monitor for updated Phase 2 pancreatic data in 1H 2027 and any financing announcements.
Price Chart
Executive Summary
Immuneering reported Q3 2026 net loss of $24.2M ($0.37 per share), wider than the $15.0M loss in Q3 2025, driven by higher R&D costs as the Phase 3 MAPKeeper 301 trial enrollment accelerates. The company highlighted positive clinical updates: Phase 2 pancreatic cancer follow-up extended because patients are living longer than projected, and Phase 3 enrollment is ahead of schedule, enabling an expansion from 510 to 570 patients with potential to accelerate the mid-2028 topline readout. Cash runway guidance was updated to Q4 2028, reflecting the expanded trial and commercial readiness activities.
Key Financial Metrics
Key Facts
- Net loss of $24.2 million for Q3 2026, compared to $15.0 million in Q3 2025
- Net loss per share of $0.37, compared to $0.38 in the prior year quarter
- Cash, cash equivalents and marketable securities of $166.1 million as of September 30, 2026
- Cash runway guidance updated to fund operations into Q4 2028
- Phase 3 MAPKeeper 301 enrollment ahead of schedule, enrollment target expanded from 510 to 570 patients
- Phase 2 pancreatic cancer trial follow-up extended; updated data expected in first half of 2027
- R&D expenses increased to $20.7 million from $10.9 million year-over-year
- GA expenses increased to $5.1 million from $4.5 million year-over-year
Financial Impact
Net loss widened by $9.2 million year-over-year to $24.2 million; cash burn rate increased significantly with R&D spend nearly doubling to $20.7 million
Risk Factors
- Cash runway now only extends to Q4 2028, potentially requiring additional financing before Phase 3 data readout in mid-2028
- R&D expenses nearly doubled year-over-year to $20.7 million, indicating rapid cash burn acceleration
- Pre-revenue clinical-stage company with no approved products and no guarantee of Phase 3 success
- Phase 2 data update delayed to 1H 2027, extending uncertainty on clinical profile
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001790340-26-000095 |
| Document: imrx-20261029.htm | 0001790340-26-000095 |
| Document: 0001790340-26-000095-index-headers.html | 0001790340-26-000095 |
| Document: 0001790340-26-000095-index.html | 0001790340-26-000095 |
| Document: 0001790340-26-000095.txt | 0001790340-26-000095 |
| 8-K Data (Synthetic) | 0001790340-26-000095 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Oct 29, 2026 3d ago | Press Release | $4.02 | awaiting T+1 | awaiting T+1 | $3.74 (−6.84%) |
Oct 26, 2026 6d ago | Press Release | $3.71 $3.83 | ▲ +3.23% | ▲ +2.67% | $3.74 (+0.94%) |
Oct 2, 2026 4w ago | Press Release | $4.07 $4.04 | ▼ −0.74% | ▼ −1.41% | $3.74 (−7.99%) |
Sep 28, 2026 4w ago | Press Release | $4.16 $4.13 | ▼ −0.72% | ▼ −0.54% | $3.74 (−9.98%) |
Aug 26, 2026 9w ago | Press Release | $5.21 $4.99 | ▼ −4.22% | ▼ −4.00% | $3.74 (−28.12%) |
Aug 5, 2026 12w ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Aug 5, 2026 12w ago | Press Release | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.74 (−14.69%) |
Jun 11, 2026 20w ago | Institutional Cluster | $4.12 $4.19 | ▲ +1.70% | ▲ +1.16% | $3.74 (−9.10%) |
Jun 1, 2026 21w ago | 8-K | $4.28 $4.55 | ▲ +6.31% | ▲ +7.00% | $3.74 (−12.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers